Bevacizumab

Phase 2Recruiting

0 views this week 0 watching💤 Quiet

Interest: 36/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Anaplastic (Malignant) Meningioma

Conditions

Anaplastic (Malignant) Meningioma, Atypical Meningioma, Grade II Meningioma, Grade III Meningioma, Recurrent Meningioma, Supratentorial Meningioma

Trial Timeline

Aug 1, 2016 → Dec 1, 2026

NCT ID

NCT02847559

About Bevacizumab

Bevacizumab is a phase 2 stage product being developed by Novocure for Anaplastic (Malignant) Meningioma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT02847559. Target conditions include Anaplastic (Malignant) Meningioma, Atypical Meningioma, Grade II Meningioma.

What happened to similar drugs?

0 of 1 similar drugs in Anaplastic (Malignant) Meningioma were approved

Approved (0) Terminated (0) Active (1)

🔄Alectinib + CrizotinibRochePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02743078	Phase 2	Terminated	May 9, 2017	Oct 15, 2019	Glioblastoma
NCT02663271	Phase 2	Terminated	Dec 19, 2016	Jun 11, 2021	Glioblastoma Multiforme
NCT02847559	Phase 2	Recruiting	Aug 1, 2016	Dec 1, 2026	Anaplastic (Malignant) Meningioma
NCT01894061	Phase 2	Completed	Sep 18, 2013	Jul 1, 2019	Adult Giant Cell Glioblastoma

Competing Products

20 competing products in Anaplastic (Malignant) Meningioma

See all competitors

Product	Company	Stage	Hype Score
CS-7017 + Paclitaxel	Daiichi Sankyo	Phase 1/2	24
efatutazone + paclitaxel	Daiichi Sankyo	Phase 2	35
Lenvatinib 24 mg	Eisai	Phase 2	27
Lenvatinib + Nivolumab	Ono Pharmaceutical	Phase 2	39
durvalumab + tremelimumab	AstraZeneca	Phase 1	29
Pembrolizumab	Merck	Phase 2	35
LDK378 + AUY922	Novartis	Phase 1	29
ceritinib	Novartis	Pre-clinical	30
LDK378	Novartis	Phase 1	29
Ceritinib	Novartis	Phase 2	27
Gemcitabine + ribociclib + sonidegib + trametinib + filgrastim	Novartis	Phase 1	29
dabrafenib/trametinib	Novartis	Phase 2	42
Trametinib + Paclitaxel	Novartis	Phase 1	33
Alectinib + Crizotinib	Roche	Phase 3	44
Sunitinib Malate	Pfizer	Phase 2	35
Crizotinib (PF-02341066)	Pfizer	Phase 2	35
Lorlatinib	Pfizer	Phase 2	31
Crizotinib	Pfizer	Phase 1/2	32
Cemiplimab + XL092	Regeneron Pharmaceuticals	Phase 1	36
Etirinotecan pegol	Nektar Therapeutics	Phase 2	29